Features of Hepatitis C Virus Infection, Current Therapies and Ongoing Clinical Trials in Ten Asian Pacific Countries

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2015 May 6

PMID 25941137

Citations 13

Authors

Masao Omata

Tatsuo Kanda

Osamu Yokosuka

Darrell Crawford

Mamun Al-Mahtab

Lai Wei

Alaaeldin Ibrahim

George K K Lau

Barjesh C Sharma

Saeed S Hamid

Wan-Long Chuang

A Kadir Dokmeci

Affiliations

Soon will be listed here.

Abstract

Estimated hepatitis C virus (HCV) infection rates in the general populations were 1.3, 0.9, 0.4-1.0, 14.7, 0.1-0.3, 0.9-1.9, 1.0-2.0, 5, 4.4-8.6 and 0.5-1.3 % in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. The main HCV genotypes (Gs) are G1, G3, G1b, G4, G1b, G3, G1b, G3, G1b and G2, and G1 in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. Of IL28B genotypes, favorable alleles are ~50 % in Australia and Turkey, but 60-70 % in most of the other Asian countries. Peginterferon plus ribavirin is available in all ten Asian Pasific countries. In addition, HCV NS3/4A protease inhibitors with peginterferon plus ribavirin are currently available in several countries. Clinical trials of interferon-free regimens for HCV are ongoing in most of the ten Asian Pacific countries.

Citing Articles

Asian Perspective on Hepatitis B Virus and Hepatitis C Virus Elimination.

Kaewdech A, Charatcharoenwitthaya P, Piratvisuth T Viruses. 2025; 17(1.

PMID: 39861823 PMC: 11768638. DOI: 10.3390/v17010034.

Hepatitis C Virus-Pediatric and Adult Perspectives in the Current Decade.

Kerkar N, Hartjes K Pathogens. 2025; 14(1).

PMID: 39860972 PMC: 11769290. DOI: 10.3390/pathogens14010011.

Epidemiology and Risk Factors for Acute Viral Hepatitis in Bangladesh: An Overview.

Kayesh M, Kohara M, Tsukiyama-Kohara K Microorganisms. 2022; 10(11).

PMID: 36422336 PMC: 9695917. DOI: 10.3390/microorganisms10112266.

Chronic Infection with Hepatitis C Virus Subtype 1g in a Japanese Patient Successfully Treated with Glecaprevir/Pibrentasvir.

Hatanaka T, Kakizaki S, Kaburagi T, Saito N, Nakano S, Hazama Y Intern Med. 2021; 61(10):1537-1543.

PMID: 34897154 PMC: 9177357. DOI: 10.2169/internalmedicine.8673-21.

Hepatitis C Virus Subtypes Novel 6g-Related Subtype and 6w Could Be Indigenous in Southern Taiwan with Characteristic Geographic Distribution.

Tung H, Lee P, Chen J, Kuo H, Sheu M, Cheng C Viruses. 2021; 13(7).

PMID: 34372521 PMC: 8310057. DOI: 10.3390/v13071316.

References

Roberts S, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G . Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. J Gastroenterol Hepatol. 2013; 29(1):179-84. DOI: 10.1111/jgh.12424. View

Yu M, Chuang W, Chen S, Dai C, Hou C, Wang J . Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. J Med Virol. 2001; 65(1):58-65. View

Cuadros D, Branscum A, Miller F, Abu-Raddad L . Spatial epidemiology of hepatitis C virus infection in Egypt: analyses and implications. Hepatology. 2014; 60(4):1150-9. PMC: 4282472. DOI: 10.1002/hep.27248. View

Williams T, Wonke B, Donohue S . A study of hepatitis B and C prevalence and liver function in multiply transfused thalassemic and their parents. Indian Pediatr. 1992; 29(9):1119-24. View

Abdelwahab S, Hashem M, Galal I, Sobhy M, Abdel-Ghaffar T, Galal G . Incidence of hepatitis C virus infection among Egyptian healthcare workers at high risk of infection. J Clin Virol. 2013; 57(1):24-8. DOI: 10.1016/j.jcv.2013.01.005. View

Bozdayi A, Aslan N, Bozdayi G, Turkyilmaz A, Sengezer T, Wend U . Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol. 2004; 149(11):2115-29. DOI: 10.1007/s00705-004-0363-2. View

Rao H, Wei L, Lopez-Talavera J, Shang J, Chen H, Li J . Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2013; 29(3):545-53. PMC: 4272577. DOI: 10.1111/jgh.12398. View

Ahmed B, Ali T, Qureshi H, Hamid S . Population-attributable estimates for risk factors associated with hepatitis B and C: policy implications for Pakistan and other South Asian countries. Hepatol Int. 2015; 7(2):500-7. DOI: 10.1007/s12072-012-9417-9. View

Rodriguez-Torres M, Stoehr A, Gane E, Serfaty L, Lawitz E, Zhou A . Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clin Gastroenterol Hepatol. 2013; 12(6):1029-37.e5. DOI: 10.1016/j.cgh.2013.09.067. View

10.

Morikawa H, Kozuka R, Fujii H, Iwai S, Enomoto M, Tamori A . Combination therapy of natural human interferon-beta and ribavirin for chronic hepatitis C patients with injection drug use. Hepatol Res. 2013; 43(10):1013-9. DOI: 10.1111/hepr.12066. View

11.

Mumtaz K, Hamid S, Moatter T, Abid S, Shah H, Jafri W . Distribution of hepatitis C virus genotypes and its response to treatment in Pakistani patients. Saudi Med J. 2008; 29(11):1671-3. View

12.

Yu M, Chuang W, Wang L, Dai C, Chiou S, Sung M . Status and natural course of GB virus C/hepatitis G virus infection among high-risk groups and volunteer blood donors in Taiwan. J Gastroenterol Hepatol. 2001; 15(12):1404-10. DOI: 10.1046/j.1440-1746.2000.02359.x. View

13.

Masvidal Aliberch R, Estabanell Buxo A, Miguel Gil B, Cruz Rodriguez C, de Frutos Gallego E, Guzman Molina C . [Indication of determination of antibodies against hepatitis C and A viruses in the protocol for the care of young immigrants]. Gac Sanit. 2010; 24(4):288-92. DOI: 10.1016/j.gaceta.2009.10.013. View

14.

Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H . Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014; 49(5):941-53. DOI: 10.1007/s00535-014-0949-8. View

15.

Yang J, Lin C, Huang J, Dai C, Lin W, Ho C . Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci. 2010; 26(9):461-9. DOI: 10.1016/S1607-551X(10)70073-5. View

16.

Khodabandehloo M, Roshani D, Sayehmiri K . Prevalence and trend of hepatitis C virus infection among blood donors in Iran: A systematic review and meta-analysis. J Res Med Sci. 2014; 18(8):674-82. PMC: 3872606. View

17.

Lai M, Kao J, Yang P, Wang J, Chen P, Chan K . Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 1996; 111(5):1307-12. DOI: 10.1053/gast.1996.v111.pm8898645. View

18.

Agarwal S, Dash S, Irshad M . Hepatitis C virus infection during haemodialysis in India. J Assoc Physicians India. 2001; 47(12):1139-43. View

19.

Rudra S, Chakrabarty P, Poddar B . Prevalence of hepatitis B and hepatitis C virus infection in human of Mymensingh, Bangladesh. Mymensingh Med J. 2011; 20(2):183-6. View

20.

Takano S, Nakamura K, Kawai S, Yokosuka O, Satomura Y, Omata M . Prospective assessment of donor blood screening for antibody to hepatitis C virus by first- and second-generation assays as a means of preventing posttransfusion hepatitis. Hepatology. 1996; 23(4):708-12. DOI: 10.1053/jhep.1996.v23.pm0008666321. View